Table 2.

Change in Dermatology Life Quality Index scores from baseline through week 24

	Placebo	Guselkumab	Adalimumab
Patients randomized at week 0, N	422	825	582
Week 8
N	418	817	575
Mean ± SD	− 1.7 ± 5.9	− 9.6 ± 6.7	− 8.8 ± 6.8
Median	− 2.0	− 9.0	− 8.0
p value vs. placebo		< 0.001	< 0.001
Week 16
N	418	817	575
Mean ± SD	− 1.8 ± 6.7	− 11.3 ± 7.0	− 9.5 ± 7.4
Median	− 1.0	− 11.0	− 9.0
p value vs. placebo		< 0.001	< 0.001
Week 24
N	NA	817	575
Mean ± SD	NA	− 11.8 ± 7.2	− 9.6 ± 7.7
Median	NA	− 12.0	− 9.0
p value vs. adalimumab		< 0.001

NA not applicable, SD standard deviation